98 related articles for article (PubMed ID: 30029312)
1. Environmental superbugs: The case study of Pedobacter spp.
Viana AT; Caetano T; Covas C; Santos T; Mendo S
Environ Pollut; 2018 Oct; 241():1048-1055. PubMed ID: 30029312
[TBL] [Abstract][Full Text] [Related]
2. [Investigation of the susceptibilities of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella spp. strains to ertapenem and other carbapenems].
Kuzucu C; Yetkin F; Görgeç S; Ersoy Y
Mikrobiyol Bul; 2011 Jan; 45(1):28-35. PubMed ID: 21341156
[TBL] [Abstract][Full Text] [Related]
3. Pharmacodynamic modeling of carbapenems and fluoroquinolones against bacteria that produce extended-spectrum beta-lactamases.
Moczygemba LR; Frei CR; Burgess DS
Clin Ther; 2004 Nov; 26(11):1800-7. PubMed ID: 15639692
[TBL] [Abstract][Full Text] [Related]
4. [In vitro emergence of ertapenem resistance in Escherichia coli producing extended-spectrum β-lactamase].
Villar HE; Jugo MB; Visser M; Hidalgo M; Hidalgo G; Maccallini GC
Rev Esp Quimioter; 2014 Mar; 27(1):51-5. PubMed ID: 24676243
[TBL] [Abstract][Full Text] [Related]
5. Whole genome sequencing and antibiotic diffusion assays, provide new insight on drug resistance in the genus Pedobacter.
Ullmann IF; Nygaard AB; Tunsjø HS; Charnock C
FEMS Microbiol Ecol; 2020 Jun; 96(6):. PubMed ID: 32386210
[TBL] [Abstract][Full Text] [Related]
6. In vitro susceptibility of recent antibiotic-resistant urinary pathogens to ertapenem and 12 other antibiotics.
Alhambra A; Cuadros JA; Cacho J; Gómez-Garcés JL; Alós JI
J Antimicrob Chemother; 2004 Jun; 53(6):1090-4. PubMed ID: 15117925
[TBL] [Abstract][Full Text] [Related]
7. Bactericidal activities of meropenem and ertapenem against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model.
DeRyke CA; Banevicius MA; Fan HW; Nicolau DP
Antimicrob Agents Chemother; 2007 Apr; 51(4):1481-6. PubMed ID: 17283197
[TBL] [Abstract][Full Text] [Related]
8. Pharmacodynamic profiling of imipenem, meropenem and ertapenem against clinical isolates of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella spp. from Brazil.
Kiffer CR; Kuti JL; Eagye KJ; Mendes C; Nicolau DP
Int J Antimicrob Agents; 2006 Oct; 28(4):340-4. PubMed ID: 16930951
[TBL] [Abstract][Full Text] [Related]
9. Influence of Different Peritoneal Dialysis Fluids on the In Vitro Activity of Cefepime, Ciprofloxacin, Ertapenem, Meropenem and Tobramycin Against Escherichia Coli.
Kussmann M; Schuster L; Wrenger S; Pichler P; Reznicek G; Burgmann H; Poeppl W; Zeitlinger M; Wiesholzer M
Perit Dial Int; 2016 11-12; 36(6):662-668. PubMed ID: 27680756
[TBL] [Abstract][Full Text] [Related]
10. What Is the Appropriate Meropenem MIC for Screening of Carbapenemase-Producing Enterobacteriaceae in Low-Prevalence Settings?
Fattouh R; Tijet N; McGeer A; Poutanen SM; Melano RG; Patel SN
Antimicrob Agents Chemother; 2015 Dec; 60(3):1556-9. PubMed ID: 26711746
[TBL] [Abstract][Full Text] [Related]
11. Comparison of disk diffusion, Etest and VITEK2 for detection of carbapenemase-producing Klebsiella pneumoniae with the EUCAST and CLSI breakpoint systems.
Vading M; Samuelsen Ø; Haldorsen B; Sundsfjord AS; Giske CG
Clin Microbiol Infect; 2011 May; 17(5):668-74. PubMed ID: 20649801
[TBL] [Abstract][Full Text] [Related]
12. Susceptibility of European Escherichia coli clinical isolates from intra-abdominal infections, extended-spectrum β-lactamase occurrence, resistance distribution, and molecular characterization of ertapenem-resistant isolates (SMART 2008-2009).
Hawser SP; Bouchillon SK; Lascols C; Hackel M; Hoban DJ; Badal RE; Cantón R
Clin Microbiol Infect; 2012 Mar; 18(3):253-9. PubMed ID: 21635662
[TBL] [Abstract][Full Text] [Related]
13. In vitro susceptibility pattern of cephalosporin-resistant Gram-negative bacteria.
Punpanich W; Tantichattanon W; Wongwatcharapaiboon S; Treeratweeraphong V
J Med Assoc Thai; 2008 Oct; 91 Suppl 3():S21-7. PubMed ID: 19255989
[TBL] [Abstract][Full Text] [Related]
14. Mutation prevention concentration of ceftriaxone, meropenem, imipenem, and ertapenem against three strains of Streptococcus pneumoniae.
Hovde LB; Rotschafer SE; Ibrahim KH; Gunderson B; Hermsen ED; Rotschafer JC
Diagn Microbiol Infect Dis; 2003 Apr; 45(4):265-7. PubMed ID: 12729997
[TBL] [Abstract][Full Text] [Related]
15. Ertapenem resistance among Klebsiella and Enterobacter submitted in the UK to a reference laboratory.
Woodford N; Dallow JW; Hill RL; Palepou MF; Pike R; Ward ME; Warner M; Livermore DM
Int J Antimicrob Agents; 2007 Apr; 29(4):456-9. PubMed ID: 17293088
[TBL] [Abstract][Full Text] [Related]
16. In vitro evaluation of different antimicrobial combinations against carbapenemase-producing Klebsiella pneumoniae: the activity of the double-carbapenem regimen is related to meropenem MIC value.
Oliva A; Scorzolini L; Cipolla A; Mascellino MT; Cancelli F; Castaldi D; D'Abramo A; D'Agostino C; Russo G; Ciardi MR; Mastroianni CM; Vullo V
J Antimicrob Chemother; 2017 Jul; 72(7):1981-1984. PubMed ID: 28369424
[TBL] [Abstract][Full Text] [Related]
17. Comparative in vitro activity of ertapenem against extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolated in Spain.
Hernández JR; Velasco C; Romero L; Martínez-Martínez L; Pascual A
Int J Antimicrob Agents; 2006 Nov; 28(5):457-9. PubMed ID: 17008066
[TBL] [Abstract][Full Text] [Related]
18. Susceptibilities of ESBL-producing Enterobacteriaceae to ertapenem, meropenem and piperacillin-tazobactam with and without clavulanic acid.
Raveh D; Yinnon AM; Broide E; Rudensky B
Chemotherapy; 2007; 53(3):185-9. PubMed ID: 17347564
[TBL] [Abstract][Full Text] [Related]
19. Pharmacodynamic activity of ertapenem versus genotypically characterized extended-spectrum β-lactamase (ESBL)-, KPC- or NDM-producing Escherichia coli with reduced susceptibility or resistance to ertapenem using an in vitro model.
Zhanel GG; Denisuik A; Vashisht S; Yachison C; Adam HJ; Hoban DJ
J Antimicrob Chemother; 2014 Sep; 69(9):2448-52. PubMed ID: 24827891
[TBL] [Abstract][Full Text] [Related]
20. Collateral damage of flomoxef therapy: in vivo development of porin deficiency and acquisition of blaDHA-1 leading to ertapenem resistance in a clinical isolate of Klebsiella pneumoniae producing CTX-M-3 and SHV-5 beta-lactamases.
Lee CH; Chu C; Liu JW; Chen YS; Chiu CJ; Su LH
J Antimicrob Chemother; 2007 Aug; 60(2):410-3. PubMed ID: 17576696
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]